Core - Core

Kosten, Thomas R.

Abstract

The Yale Medications Development Research Center (YMDRC) Core supports centralized coordination for projects representing six research themes, for interdisciplinary collaboration, and for training opportunities. The six drug treatment themes are: 1. inpatient human laboratory evaluations to predict pharmacotherapeutic efficacy, 2. pharmacokinetic assessments including interactions of new medications with abused drugs such as cocaine, 3. evaluations of abuse liability and performance effects of new treatment, 4. outpatient trials of pharmacological efficacy, 5. outpatient trials of combined behavioral and pharmacological treatments, 6. special target group studies of female substance abusers. These themes are embodied in 9 research projects that involve extensive interdisciplinary collaboration among psychiatry, psychology, pharmacology, laboratory medicine, nuclear medicine and health care economics. During the last 4 years of our Treatment Research Unit (TRU) we have generated 19 independently funded research grants including career awards and provided extensive training opportunities in drug abuse psychopharmacology for medical students, psychiatry residents, fellows and junior faculty. In addition, the TRU has been extremely productive with over 700 patients involved in over 30 research protocols resulting in over 50 papers and chapters and 60 presentations at professional meetings.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute on Drug Abuse (NIDA)
• Type: Specialized Center (P50)
• Project #: 5P50DA009250-03
• Application #: 5209737
• Support Year: 3
• Fiscal Year: 1996

Publications

Chawarski, Marek C; Fiellin, David A; O'Connor, Patrick G et al. (2007) Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. J Subst Abuse Treat 33:411-5

Chawarski, Marek C; Moody, David E; Pakes, Juliana et al. (2005) Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat 29:307-12

Kosten, Thomas R; Fiellin, David A; U.S. National Buprenorphine Implementation Program (2004) Buprenorphine for office-based practice: consensus conference overview. Am J Addict 13 Suppl 1:S1-7

Kosten, Thomas; Oliveto, Alison; Feingold, Alan et al. (2003) Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 70:315-25

Sofuoglu, Mehmet; Gonzalez, Gerardo; Poling, James et al. (2003) Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse 29:713-27

Kosten, Thomas; Poling, James; Oliveto, Alison (2003) Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction 98:665-71

Stine, Susan M; Southwick, Steven M; Petrakis, Ismene L et al. (2002) Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 51:642-51

Stine, S M; Grillon, C G; Morgan 3rd, C A et al. (2001) Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychopharmacology (Berl) 154:274-81

Jacobsen, L K; Southwick, S M; Kosten, T R (2001) Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 158:1184-90

Gottschalk, C; Beauvais, J; Hart, R et al. (2001) Cognitive function and cerebral perfusion during cocaine abstinence. Am J Psychiatry 158:540-5